FDA, EU To Redouble Inspection Of Asian Pharmaceutical Supply Chains

Mutual recognition agreement enables US and European authorities to redirect inspectional resources to China and India. The result could be more warning letters and other actions unless global companies strengthen oversight of ingredient suppliers and contract manufacturers in Asia, current and former FDA officials say.

Pharmaceutical companies should prepare for increased scrutiny of their Asian contract manufacturers and ingredient suppliers now that US and EU authorities have reached agreement on drug GMP inspections.

In coming months, the recently signed mutual recognition agreement will allow US FDA to redirect inspectional resources from Europe to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet